Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2007-06-18 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 3B 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) announcement used to notify the market of a new issue of securities, application for quotation of additional securities, or agreement related to securities. The text details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including number of shares, issue price, and dates. This is a capital raising or share issuance announcement rather than a financial report or other type of filing. It does not contain financial statements or management discussion, nor is it a report publication or certification. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2007-06-18 English
Change of Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the sale and exercise of options by a director, including dates, number of securities before and after the change, and consideration amounts. This is a report of personal share transactions by a company director. It does not contain financial statements or company-wide financial data, nor is it an announcement of a report or a certification. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is 6855 characters, sufficient to contain detailed transaction information, supporting this classification.
2007-06-18 English
Appendix 3B 10 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used to announce new issues of securities, applications for quotation of additional securities, and related agreements. It details the issuance of unlisted employee options, including number, exercise price, expiry, vesting, and purpose. This type of document is a capital/financing update as it relates to changes in the company's capital structure through issuance of new securities. It is not a full financial report, earnings release, or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a substantive announcement, not a brief notice or report publication announcement.
2007-06-17 English
Appendix 3B: Exercise of Employee Options 9 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements. The text includes details about the issue of fully paid ordinary shares upon exercise of options under an employee option plan, the number of securities issued, issue price, and other related information. This type of document is a capital/financing update rather than a full financial report or earnings release. It is not an annual report, interim report, or earnings release, nor is it a regulatory filing or announcement of a report publication. The document is clearly about a capital raising or share issue event, fitting the Capital/Financing Update category.
2007-06-04 English
Aridol Gains European Aproval 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 4 June 2007 announcing that Pharmaxis' asthma product Aridol has gained European approval. It is a press release-style announcement describing the regulatory approval and marketing authorization in multiple European countries. There are no financial statements, detailed financial performance data, or management discussion of financial results. The document is not a report itself but an announcement of a regulatory milestone and product approval. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is a general regulatory announcement about product approval and market authorization, which fits best under Regulatory Filings (RNS). The document length is 5749 characters, which is not extremely short, but the content is clearly an announcement rather than a report. Therefore, the most appropriate classification is Regulatory Filings (RNS) with high confidence.
2007-06-03 English
First Patient Enrols in Aridol COPD Trial 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 15 May 2007 from Pharmaxis announcing the enrollment of the first patient in a clinical trial for Aridol in COPD. It is a press release providing information about a clinical trial start, not a financial report, regulatory filing, or any of the other specific filing types. There is no financial data, no mention of shareholder votes, no management changes, no earnings or annual report content. The document is a public announcement of a clinical trial event, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2007-05-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.